Dendritic Cell-Based Immunotherapy of Breast Cancer: Modulation by CpG DNA
Abstract
Breast cancer is the most common non-skin cancer in women, and the American Cancer, Society estimates that there will be 203,500 new cases of invasive breast cancer and 40,000 deaths from metastatic breast cancer (MBC in the U.S. in 2002. Thus, patients with MBC who fail conventional therapies are candidates for clinical trials using novel therapies, including immunotherapy. Dendritic cells (DC) are potent antigen- presenting calls that prime antitumor cytotoxic T lymphocytes against tumor-associated antigens and bacterial DNA oligodeoxynucleotides containing unmethylated CpG sequences (CpG DNA) further augment the immune priming functions of DCs. We hypothesize that CpG DNA-stimulated DCs will prime a more potent anti-tumor immune response than non- stimulated DCs.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2002
- Accession Number
- ADA412155
Entities
People
- Joseph Baar
Organizations
- University of Pittsburgh